Alnylam Pharmaceuticals
Tracked across 4 events · 32 articles · First seen Apr 29, 2026 · Last active Aug 16, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Alnylam is the subject of the investigation and the company that cut its revenue guidance, causing a 28% stock drop. The guidance reduction and subsequent investigation negatively impact its financial outlook and investor confidence.
Jul 30, 2026 · 13 articles
Business
Impact: David Butler's earlier career at Alnylam contributed to LNP technology. Mentioned as background, no direct impact.
Aug 03, 2026 · 6 articles
Tech
Impact: Alnylam Pharmaceuticals is mentioned as the former employer of panelist John Maraganore.
Apr 29, 2026 · 7 articles
Regulatory
Impact: Alnylam licensed AG-236 to Agios, an siRNA therapy for polycythemia vera, part of Agios' broader pipeline.
Jul 07, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Alnylam Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard